The inferior performance of [68Ga]Ga-FAPI-04 PET/CT as a diagnostic and theranostic biomarker in [177Lu]Lu-DOTATATE refractory well-differentiated neuroendocrine tumors-Reference-Cited by-同舟云学术

The inferior performance of [68Ga]Ga-FAPI-04 PET/CT as a diagnostic and theranostic biomarker in [177Lu]Lu-DOTATATE refractory well-differentiated neuroendocrine tumors

Published:2023-11-10 Issue:3 Volume:51 Page:828-840
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Has Simsek Duygu^ORCID,Guzel Yunus^ORCID,Denizmen Dilara^ORCID,Sanli Yasemin^ORCID,Buyukkaya Fikret^ORCID,Kovan Bilal^ORCID,Komek Halil^ORCID,Isik Emine Goknur^ORCID,Ozkan Zeynep Gozde^ORCID,Kuyumcu Serkan^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06497-6.pdf

Reference39 articles.

1. Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia. 2017;19:991–1002.

2. Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Nat Compr Canc Netw. 2021;19:839–68.

3. Wolin EM. The expanding role of somatostatin analogs in the management of neuroendocrine tumors. Gastrointes Cancer Res: GCR. 2012;5:161.

4. Zappi A, Persano I, Galvani L, Parlagreco E, Andrini E, Campana D, et al. Chemotherapy in well differentiated neuroendocrine tumors (NET) G1, G2, and G3: a narrative review. J Clin Med. 2023;12:717.

5. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnostic Performances of PET/CT Using Fibroblast Activation Protein Inhibitors in Patients with Primary and Metastatic Liver Tumors: A Comprehensive Literature Review;International Journal of Molecular Sciences;2024-06-29